In a DC-transfer model of allergy, exposure of OVA-pulsed bone marrow-derived DCs (BMDCs) to the synthetic PPAR-γ agonist rosiglitazone reduced T cell proliferation in draining lymph nodes (LNs) and promoted IL-10 release by antigen specific T cells [79]. This evidence concerns the gene PPARG and allergic disease.